Abstract:Each of the three BAFF receptors (BCMA, TACI and BR3) has a non‐redundant role in determining the ultimate lymphocyte profile of the host, including the distribution of B cell subsets and the expansion of Foxp3+ cells. This may have clinically relevant ramifications in that the degree that a candidate therapeutic agent blocks engagement of any given individual BAFF receptor may affect its clinical utility. BAFF, a vital B cell survival and differentiation factor, has three receptors: B‐cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI) and BR3. Although B cells are greatly reduced in B6.Baff−/− (which harbour no BAFF) and B6.Br3−/− mice (which harbour supra‐normal levels of BAFF), the distributions of B cell subsets and relationships between Foxp3+ and CD4+ cells in these mice differ. Using a large panel of B6 congenic knockout and/or transgenic mice, we demonstrate that (1) supra‐normal levels of BAFF per se do not explain the phenotypic differences between B6.Baff−/− and B6.Br3−/− mice; (2) B cells are expanded in B6.Taci−/− mice, with preferential expansion of follicular (FO) B cells at the expense of CD19+CD21−/loCD23−/lo B cells but without the preferential expansion of Foxp3+ cells observed in B6 mice bearing a Baff transgene; (3) despite no expansion in total B cells, percentages of FO B cells and marginal zone B cells are higher and percentages of CD19+CD21−/loCD23−/lo B cells are lower in young B6.Bcma−/− mice, consistent with the inability of B6.Br3−/−.Taci−/− mice to recapitulate the B cell profile of B6.Baff−/− mice; and (4) percentages of Foxp3+ cells in B6.Br3−/−.Taci−/− mice are intermediate between those in B6.Br3−/− and B6.Taci−/− mice despite the B cell profile of B6.Br3−/−.Taci−/− mice strongly resembling that of B6.Br3−/− mice. Collectively, our findings point to a non‐redundant role for each of the BAFF receptors in determining the ultimate lymphocyte profile of the host. This may have clinically relevant ramifications in that the degree that a candidate therapeutic agent blocks engagement of any given individual BAFF receptor may affect its clinical utility.

Different regulatory effects of CD40 ligand and B-cell activating factor on the function of B cells

BAFF Promotes FLS Activation Through BAFFR-Mediated Non-canonical NF-κB Pathway and the Effects of CP-25.

Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10–Producing Regulatory B Cells

Contributions of each of the BAFF receptors to the lymphocyte profiles in C57BL/6 mice

BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal

BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

CD40-miRNA axis controls prospective cell fate determinants during B cell differentiation

Regulation of B‐cell function and expression of CD11c, T‐bet, and FcRL5 in response to different activation signals

Negative Regulation of Cd40-Mediated B Cell Responses by E3 Ubiquitin Ligase Casitas-B-Lineage Lymphoma Protein-B

B cell activating factor (BAFF) selects IL-10−B cells over IL-10+B cells during inflammatory responses

The Effects of CD40L on the Phenotypes and IL-12 Secretion of B Lymphocytes

Regulatory B cells:research advances

A Tetrameric Form of CD40 Ligand with Potent Biological Activities in Both Mouse and Human Primary B Cells.

Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purified human B cells

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

Regulation of Bcl-Xl Expression and Fas Susceptibility in Mouse B Cells by CD40 Ligation, Surface IgM Crosslinking and IL-4.

B Cell-Activating Factor and Its Targeted Therapy in Autoimmune Diseases.

BAFF-driven NLRP3 inflammasome activation in B cells

Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus

Effect of CD40-P227A Polymorphism at Human B Cell Signaling Pathways

Elucidating synergistic and antagonistic effects of B cell receptor and toll-like receptors 3, 4, and 9 in B cell activation